Targeted Therapy Treatment Innovations in AML : Episode 2

Video

August 26, 2021

Role of Second Generation FLT3 Inhibitors in AML

Author(s):

Expert examines the status of second-generation FLT3 inhibitors in newly diagnosed AML patients and the challenge with comparing clinical trial efficacy endpoints.

EP: 1.Role of First Generation FLT3 Inhibitors in AML

Now Viewing

EP: 2.Role of Second Generation FLT3 Inhibitors in AML

EP: 3.Part 1: IDH1 & IDH2 Inhibitors In Newly Diagnosed AML

EP: 4.Part 2: IDH1 & IDH2 Inhibitors In Newly Diagnosed AML

EP: 5.Role of Venetoclax in Treatment of AML

EP: 6.Part 1: Practical Considerations For Venetoclax in AML

EP: 7.Part 2: Practical Considerations For Venetoclax in AML

EP: 8.5-Year Follow-Up Data For CPX-351 in AML

EP: 9.CPX-351 in Clinical Practice For AML

Related Content

Sickle cell disease -- Image credit: Iftikhar alam | stock.adobe.com

October 28th 2024

FDA Grants Orphan Drug Designation to AND017 for the Treatment of Sickle Cell Disease

Gillian McGovern, Assistant Editor

January 29th 2024

Pharmacy Focus Oncology: Advancements in Hematology and Breast Cancer - ASH and SABCS 2023 Recap

Acute lymphocytic leukemia -- Image credit: jarun011 | stock.adobe.com

October 18th 2024

Inotuzumab Ozogamicin in Pediatric Patients With Relapsed or Refractory B-Cell ALL

Basmah Zahid, PharmD, MS

September 26th 2022

Pharmacy Focus: Oncology Edition - Experts See Promising Future for the Treatment of Acute Lymphoblastic Leukemia

Sarcoma -- Image credit: Saiful52 | stock.adobe.com

October 17th 2024

Removing Mesna From Cyclophosphamide Cycles in VAdriaC-IE for Ewing Sarcoma

Hunter Sowell, PharmD Colleen McCabe, PharmD, BCOP Manuel Cortez, PharmD, BCOP Rachel Gilmore, PharmD Elizabeth Davis, MD Vicki Keedy, MD

October 11th 2024

FDA Approves Marstacimab-hncq for Adults, Adolescents With Hemophilia A or B Without Inhibitors

Aislinn Antrim, Assistant Managing Editor